Alnylam Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-24$290.70 RISE2025-04-08$224.32 PEAK2025-07-03$331.91 101d | -22.8% 15d | Missed | Missed | — | — | +48.0% 86d | Missed |
DROP2024-10-16$300.55 RISE2025-01-06$233.15 PEAK2025-03-24$290.70 159d | -22.4% 82d | Missed | Missed | — | — | +24.7% 77d | Missed |
DROP2024-10-16$300.55 RISE2024-11-18$232.27 PEAK2025-01-28$279.19 104d | -22.7% 33d | Missed | Missed | — | — | +20.2% 71d | Missed |
DROP2024-01-09$198.20 RISE2024-04-26$143.31 PEAK2024-07-11$261.02 184d | -27.7% 108d | Missed | Missed | — | — | +82.1% 76d | Missed |
DROP2023-09-13$211.65 RISE2023-10-30$151.41 PEAK2024-01-09$198.20 118d | -28.5% 47d | Missed | Missed | — | — | +30.9% 71d | Missed |
DROP2023-05-05$212.05 RISE2023-08-15$180.13 PEAK2023-09-12$211.65 130d | -15.1% 102d | Missed | Missed | — | — | +17.5% 28d | Missed |
DROP2022-12-21$241.31 RISE2023-03-10$182.66 PEAK2023-05-05$212.05 135d | -24.3% 79d | Missed | Missed | — | — | +16.1% 56d | Missed |
DROP2022-08-12$233.85 RISE2022-10-12$185.11 PEAK2022-12-21$241.31 131d | -20.8% 61d | Missed | Missed | — | — | +30.4% 70d | Missed |
DROP2022-01-03$173.91 RISE2022-05-11$120.42 PEAK2022-08-08$230.74 217d | -30.8% 128d | Missed | Missed | — | — | +91.6% 89d | Missed |
DROP2021-10-14$209.29 RISE2022-01-27$127.18 PEAK2022-04-01$169.29 169d | -39.2% 105d | Missed | Missed | — | — | +33.1% 64d | Missed |
DROP2021-10-14$209.29 RISE2021-10-29$159.56 PEAK2021-12-21$199.59 68d | -23.8% 15d | Missed | Missed | — | — | +25.1% 53d | Missed |
DROP2021-01-25$175.69 RISE2021-05-10$128.63 PEAK2021-08-04$183.44 191d | -26.8% 105d | Missed | Missed | — | — | +42.6% 86d | Missed |
DROP2021-01-25$175.69 RISE2021-03-29$133.80 PEAK2021-06-18$176.89 144d | -23.8% 63d | Missed | Missed | — | — | +32.2% 81d | Missed |
DROP2020-07-20$165.49 RISE2020-10-30$122.97 PEAK2021-01-25$175.69 189d | -25.7% 102d | Missed | Missed | — | — | +42.9% 87d | Missed |
DROP2020-07-20$165.49 RISE2020-09-10$121.19 PEAK2020-10-09$147.00 81d | -26.8% 52d | Missed | Missed | — | — | +21.3% 29d | Missed |
1–15 / 16 1 / 2 | |||||||
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 12 Best Revenue Growth Stocks to Buy According to Wall Street Analysts. On May 19, Citi initiated coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), giving the stock a Buy rating and setting the price target at $380. The research firm noted that the expanded launch of Amvuttra for […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 12 Best Revenue Growth Stocks to Buy According to Wall Street Analysts. On May 19, Citi initiated coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), giving the stock a Buy rating and setting the price target at $380. The research firm noted that the expanded launch of Amvuttra for […]
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...
CAMBRIDGE, Mass., May 19, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, "Accepting Challenges to Improve the Health of Humanity," which remains central to Alnylam’s strategy and is embedded across six
Citigroup analyst Eric Joseph initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy rating and announces Price Target of $380.
Earlier in May 2026, Alnylam Pharmaceuticals reported new HELIOS-B Phase 3 analyses showing its TTR silencer vutrisiran delivered durable transthyretin knockdown, consistent clinical benefit across high‑risk ATTR-CM subgroups, and low, placebo‑like rates of vitamin A–related ocular events over more than 25,000 patient‑years of exposure. The company also launched the large DemonsTTRate real‑world outcomes study and highlighted that worldwide experience with vutrisiran now exceeds 13,000...
Earlier in May 2026, Alnylam Pharmaceuticals reported new HELIOS-B Phase 3 analyses showing its TTR silencer vutrisiran delivered durable transthyretin knockdown, consistent clinical benefit across high‑risk ATTR-CM subgroups, and low, placebo‑like rates of vitamin A–related ocular events over more than 25,000 patient‑years of exposure. The company also launched the large DemonsTTRate real‑world outcomes study and highlighted that worldwide experience with vutrisiran now exceeds 13,000...
FDA leadership shake-up update and what it means for Pfizer: valuation, dividend yield, and Padcev growth.
Alnylam Pharmaceuticals (NasdaqGS:ALNY) reported new Phase 3 HELIOS-B analyses for vutrisiran in ATTR-CM. The data show reductions in all-cause mortality and cardiovascular events, including in high-risk subgroups. Safety findings support a favorable profile for vutrisiran, the first and only approved TTR silencer for ATTR-CM. Alnylam is also launching the DemonsTTRate real-world outcomes study to assess long-term impact in routine clinical practice. Alnylam focuses on RNA interference...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) reported new Phase 3 HELIOS-B analyses for vutrisiran in ATTR-CM. The data show reductions in all-cause mortality and cardiovascular events, including in high-risk subgroups. Safety findings support a favorable profile for vutrisiran, the first and only approved TTR silencer for ATTR-CM. Alnylam is also launching the DemonsTTRate real-world outcomes study to assess long-term impact in routine clinical practice. Alnylam focuses on RNA interference...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $510 on the stock. This update came after the company reported Q1 results. The company reported […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $510 on the stock. This update came after the company reported Q1 results. The company reported […]
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALNY | +1.98% | -7.10% | -24.06% | -0.85% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -0.99% | -1.39% | -20.62% | -13.54% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 14.58M | $4.82B | 0.25% | Trimmed-8.3% | 2026-03-31 |
| CapResearch | fundamental | 9.47M | $3.13B | 0.49% | Added+39.7% | 2026-03-31 |
| StateStreet | passive | 3.32M | $1.10B | 0.04% | Added+2.9% | 2026-03-31 |
| TwoSigma | quant | 1.99M | $659.28M | 0.53% | Added+223.4% | 2026-03-31 |
| Wellington | fundamental | 1.94M | $640.54M | 0.12% | Added+18.8% | 2026-03-31 |
| DEShaw | quant | 1.06M | $350.41M | 0.21% | Added+138.3% | 2026-03-31 |
| Bridgewater | macro | 106.6K | $35.27M | 0.16% | Added+24.5% | 2026-03-31 |
| TRowePrice | fundamental | 1.43M | $474.06K | 0.05% | Trimmed-15.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | Arbuckle Stuart A | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | Arbuckle Stuart A | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | Ausiello Dennis A | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | Ausiello Dennis A | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | BRANDICOURT OLIVIER | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | BRANDICOURT OLIVIER | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | HAMBURG MARGARET A | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | HAMBURG MARGARET A | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | KELLOGG PETER N | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | KELLOGG PETER N | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | PYOTT DAVID E I | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | PYOTT DAVID E I | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | Reitan Colleen F | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | Reitan Colleen F | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-22 | SCHULMAN AMY W | Director | A Grant / award(deriv) | 1,802 | — | +$0 |
| 2026-05-22 | SCHULMAN AMY W | Director | A Grant / award | 838 | — | +$0 |
| 2026-05-22 | Sigal Charles Elliott | Director | A Grant / award(deriv) | 1,441 | — | +$0 |
| 2026-05-22 | Sigal Charles Elliott | Director | A Grant / award | 671 | — | +$0 |
| 2026-05-14 | SCHULMAN AMY W | Director | M Option exercise(deriv) | 11,250 | — | +$0 |
| 2026-05-14 | SCHULMAN AMY W | Director | M Option exercise | 11,250 | $70.20 | +$789.8K |
| 2026-04-07 | McLaughlin Melissa | Chief Human Resources Officer | S Open-market sale | 199 | $333.94 | −$66.5K |
| 2026-04-07 | McLaughlin Melissa | Chief Human Resources Officer | S Open-market sale | 293 | $331.89 | −$97.2K |
| 2026-04-07 | McLaughlin Melissa | Chief Human Resources Officer | S Open-market sale | 829 | $330.46 | −$274.0K |
| 2026-04-07 | McLaughlin Melissa | Chief Human Resources Officer | S Open-market sale | 909 | $329.76 | −$299.8K |
| 2026-04-07 | McLaughlin Melissa | Chief Human Resources Officer | S Open-market sale | 56 | $320.14 | −$17.9K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 2.17 | — | — |
| 2026-04-30 | 1.47 | 1.99 | +35.30% |
| 2026-02-12 | 1.50 | 1.25 | -16.50% |
| 2025-10-30 | 1.75 | 2.90 | +66.12% |
| 2025-07-31 | 0.15 | 0.32 | +119.58% |
| 2025-05-01 | -0.37 | -0.01 | +97.29% |
| 2025-02-13 | -0.14 | 0.06 | +142.52% |
| 2024-10-31 | -0.39 | -0.50 | -26.71% |
| 2024-08-01 | -0.69 | 0.56 | +181.07% |
| 2024-05-02 | -0.63 | -0.16 | +74.50% |
| 2024-02-15 | -0.77 | -0.77 | -0.20% |
| 2023-11-02 | -0.96 | 1.74 | +281.92% |
| 2023-08-03 | -1.34 | -1.62 | -21.19% |
| 2023-05-04 | -1.43 | -1.06 | +25.73% |
| 2023-02-23 | -1.48 | -1.39 | +6.28% |
| 2022-10-27 | -1.38 | -1.58 | -14.63% |